Business Description
GSK PLC
ISIN : US37733W2044
Share Class Description:
GSK: ADRTotal Employee Number:
66,841Description
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.18 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.07 | |||||
Debt-to-EBITDA | 1.82 | |||||
Interest Coverage | 12.16 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.18 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.4 | |||||
3-Year EBITDA Growth Rate | 6.3 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | -2.9 | |||||
3-Year Book Growth Rate | 16.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.85 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.01 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.85 | |||||
9-Day RSI | 57.47 | |||||
14-Day RSI | 55.62 | |||||
3-1 Month Momentum % | -8.6 | |||||
6-1 Month Momentum % | 1.9 | |||||
12-1 Month Momentum % | 34.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.79 | |||||
Quick Ratio | 0.52 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 246.77 | |||||
Days Sales Outstanding | 80.14 | |||||
Days Payable | 517.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.41 | |||||
Dividend Payout Ratio | 0.46 | |||||
3-Year Dividend Growth Rate | -5.7 | |||||
Forward Dividend Yield % | 3.41 | |||||
5-Year Yield-on-Cost % | 1.91 | |||||
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | 4.05 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.68 | |||||
Operating Margin % | 25.67 | |||||
Net Margin % | 17.78 | |||||
EBITDA Margin % | 32 | |||||
FCF Margin % | 14.53 | |||||
OCF Margin % | 23.63 | |||||
ROE % | 36.74 | |||||
ROA % | 9.55 | |||||
ROIC % | 14.03 | |||||
3-Year ROIIC % | 38.82 | |||||
ROC (Joel Greenblatt) % | 81.12 | |||||
ROCE % | 20.43 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.85 | |||||
Forward PE Ratio | 11.54 | |||||
PE Ratio without NRI | 13.85 | |||||
Shiller PE Ratio | 13.58 | |||||
Price-to-Owner-Earnings | 16.72 | |||||
PEG Ratio | 3.85 | |||||
PS Ratio | 2.47 | |||||
PB Ratio | 4.49 | |||||
Price-to-Free-Cash-Flow | 17.18 | |||||
Price-to-Operating-Cash-Flow | 10.57 | |||||
EV-to-EBIT | 11.57 | |||||
EV-to-Forward-EBIT | 10.43 | |||||
EV-to-EBITDA | 8.96 | |||||
EV-to-Forward-EBITDA | 8.52 | |||||
EV-to-Revenue | 2.87 | |||||
EV-to-Forward-Revenue | 2.85 | |||||
EV-to-FCF | 19.76 | |||||
Price-to-GF-Value | 1.21 | |||||
Price-to-Projected-FCF | 1.34 | |||||
Price-to-Median-PS-Value | 1.19 | |||||
Earnings Yield (Greenblatt) % | 8.64 | |||||
FCF Yield % | 6.03 | |||||
Forward Rate of Return (Yacktman) % | 8.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:GSK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GSK PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 44,094.635 | ||
| EPS (TTM) ($) | 3.834 | ||
| Beta | -0.074 | ||
| 3-Year Sharpe Ratio | 0.5 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 22.92 | ||
| 14-Day RSI | 55.62 | ||
| 14-Day ATR ($) | 1.207453 | ||
| 20-Day SMA ($) | 51.966 | ||
| 12-1 Month Momentum % | 34.94 | ||
| 52-Week Range ($) | 35.45 - 61.695 | ||
| Shares Outstanding (Mil) | 2,002.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GSK PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GSK PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 113 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-07-28 | In 21 days | ||
| USD 0.461074 Cash Dividend | 2026-05-15 | 50.96 (-0.55%) | ||
| General meeting for 2026 | 2026-05-06 13:30 | 50.38 (-0.14%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 11:00 | 54.47 (+0.18%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 54.47 (+0.18%) | ||
| Annual report for 2025 | 2026-03-05 | 56.83 (-0.33%) | ||
| USD 0.477611 Cash Dividend | 2026-02-20 | 60.85 (-0.13%) |
Show
Entries
GSK PLC Frequently Asked Questions
What is GSK PLC(GSK)'s stock price today?
The current price of GSK is $53.09. The 52 week high of GSK is $61.70 and 52 week low is $35.45.
When is next earnings date of GSK PLC(GSK)?
The next earnings date of GSK PLC(GSK) is 2026-07-28.
Does GSK PLC(GSK) pay dividends? If so, how much?
The Dividend Yield %  of GSK PLC(GSK) is 3.41% (As of Today), Highest Dividend Payout Ratio of GSK PLC(GSK) was 1.47. The lowest was 0.43. And the median was 0.89. The  Forward Dividend Yield % of GSK PLC(GSK) is 3.41%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:GSK
No articles.
Press Release
Articles on GSK PLC
No articles.
Headlines
See More- 1
Jul 06, 2026
WHO begins experimental Ebola trial as Congo outbreak claims 500+ lives
Seeking Alpha • 10:16am
Jun 25, 2026
Record-setting healthcare M&A activity to extend through H2: PwC
Seeking Alpha • 12:59pm
Jun 17, 2026
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
Benzinga • 12:29pm
GSK, Spero win approval of Utebzi for complicated urinary tract infections
Seeking Alpha • 10:30am
Jun 14, 2026
Top global stories this week
Seeking Alpha • 1:17pm
Jun 12, 2026
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Benzinga • 6:30am
Jun 09, 2026
Biotech stocks are losing momentum despite rising M&A activity
Seeking Alpha • 1:20pm
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
Benzinga • 5:52am
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
Seeking Alpha • 4:18am
GSK to buy Nuvalent for $10.6B
Seeking Alpha • 2:02am
GSK in talks to buy Nuvalent for over $9B - report
Seeking Alpha • 11:50pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers